Source: BMC Cancer. Unidade: FMRP
Subjects: NEOPLASIAS MAMÁRIAS, IMUNOQUÍMICA, QUIMIOTERAPIA ADJUVANTE
ABNT
ALVES, Wilson Eduardo Furlan Matos et al. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. BMC Cancer, v. 19, p. [11] , 2019Tradução . . Disponível em: https://doi.org/10.1186/s12885-019-6353-2. Acesso em: 21 ago. 2024.APA
Alves, W. E. F. M., Bonatelli, M., Dufloth, R. M., Kerr, L. M., Carrara, G. F. A., Costa, R. F. A. da, et al. (2019). CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy. BMC Cancer, 19, [11] . doi:10.1186/s12885-019-6353-2NLM
Alves WEFM, Bonatelli M, Dufloth RM, Kerr LM, Carrara GFA, Costa RFA da, Scapulatempo Neto C, Tiezzi DG, Vieira RA da C, Pinheiro CM. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy [Internet]. BMC Cancer. 2019 ; 19 [11] .[citado 2024 ago. 21 ] Available from: https://doi.org/10.1186/s12885-019-6353-2Vancouver
Alves WEFM, Bonatelli M, Dufloth RM, Kerr LM, Carrara GFA, Costa RFA da, Scapulatempo Neto C, Tiezzi DG, Vieira RA da C, Pinheiro CM. CAIX is a predictor of pathological complete response and is associated with higher survival in locally advanced breast cancer submitted to neoadjuvant chemotherapy [Internet]. BMC Cancer. 2019 ; 19 [11] .[citado 2024 ago. 21 ] Available from: https://doi.org/10.1186/s12885-019-6353-2